Black Diamond Therapeutics Q3 2021 cash $235M; BDTX-189 Phase 2 on track for year-end

Black Diamond Therapeutics, Inc.

2021-Q3 EPS reported -$2.76

Cash, equivalents, and investments $235.0M as of Sept 30, 2021; expected runway into H2 2023.
Net cash used in operations Q3 2021 was $26.5M, up from $11.5M in Q3 2020.
R&D expenses $27.6M (Q3 2021) vs $12.9M (Q3 2020), driven by headcount and preclinical/clinical costs.
BDTX-189 Phase 2 portion initiation by end of 2021; BDTX-1535 IND filing targeted H1 2022.
Preclinical data for BDTX-1535, BRAF, and FGFR programs presented at ANE conference; partnership with OpenEye Scientific.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.